Please assess the completion status of the following clinical trial:

Trial Title: Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~(1) histology-confirmed metastatic CRC (mCRC); (2) disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab; (3) fruquintinib administered as salvage treatment; (4) available clinical data.~Exclusion Criteria:~(1) lack of follow-up data; (2) fruquintinib administration as second-line treatment; (3) fruquintinib administration stopped after less than two cycles.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- monotherapy group (Type: None): patients received fruquintinib alone
- combine group (Type: None): patients administered fruquintinib in combination with chemotherapy or/and anti-PD1 antibodies

Based on this trial design, predict the completion outcome and termination type (if applicable).